Patients not adequately warned about GLP-1 drug risks: Attorney | Morning in America
Thousands of patients are suing the companies behind GLP-1 weight loss drugs, alleging they caused blindness, loss of brain function and organ damage. Jonathan Orent, an attorney representing some of the plaintiffs, tells “Morning in America” that European warning labels also include information about the risk of blindness. He argues that drugmakers have failed to […]
GLP-1 drugs might do what food policy can’t — change the way we eat
The desire for smaller portions and fewer junk foods is affecting what the food industry is selling us.
Here’s What Happens When You Stop Taking Ozempic and Wegovy – WSJ – The Wall Street Journal
Here’s What Happens When You Stop Taking Ozempic and Wegovy – WSJ The Wall Street Journal Hard truth about what happens when you stop weight loss injections Times of India Exclusive | GLP-1 drugs brought our eating disorders back — and quitting the shots doesn’t always help New York Post New Study of 77,000 Patients Reveals the Hard […]
Dr. Mark Hyman on GLP‑1 drugs facing multiple lawsuits | CUOMO
Dr. Mark Hyman returned to NewsNation to discuss the surge of lawsuits and the future of GLP‑1 drugs. Ozempic, once hailed as a “miracle” weight‑loss medication, helped drive more than 31 million Americans to GLP‑1s despite early warnings he discussed on the show in 2023. Now, thousands of lawsuits allege the drugs caused serious health […]
Starting GLP-1s Leads to Healthier Choices at Grocery Store
The initiation of GLP-1 receptor agonists is associated with modest shifts away from ultraprocessed foods and toward items with fewer calories and smaller amounts of carbs, sugar, and saturated fat. Medscape Medical News
Cold weather, hot scams.
This week, hosts Dave Bittner, Joe Carrigan, and Maria Varmazis (also host of the T-Minus Space Daily show) are sharing the latest in social engineering scams, phishing schemes, and criminal exploits that are making headlines. Joe has two stories this week, starting with scammers cashing in on a Verizon outage by luring customers with fake […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by 8%, reflecting the positive momentum. Pharmaceuticals Division sales increased by 9% (3% in CHF), with Phesgo (breast cancer), Xolair (food allergies), Ocrevus (multiple sclerosis), Hemlibra (haemophilia […]
Serena Williams refuses to rule out tennis comeback in new interview
Serena Williams has refused to rule out a tennis comeback, just under two months after she definitively denied a return to the sport in which she won 23 Grand Slam singles titles. In December, the appearance of Williams’ name in the tennis anti-doping test pool, a prerequisite to returning to the sport, raised the possibility […]
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
<div><p paraid=”1424849640″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{9}”><strong>By Irene Yeh </strong></p></div><div><p paraid=”326437554″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{15}”><strong>January 29, 2026</strong> | Earlier this month at the J.P. Morgan Healthcare Conference, Eli Lilly Chairman and CEO David Ricks spoke at a fireside chat and presented what the company has planned for 2026, which also marks its 150th anniversary. This year is expected to be a productive one in terms of clinical trial activity, wider availability of medicines, and expansion into new therapeutic areas. </p></div><div><p paraid=”1509187804″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{107}”><strong>Anti-Obesity Drugs </strong></p></div><div><p paraid=”1827316575″ […]
A small molecule PTER-selective inhibitor reduces food intake and body weight
PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remains unknown, limiting our ability to harness this pathway therapeutically. Here, we solve crystal structures of a eukaryotic PTER in apo and product-bound forms. These structures uncover an unexpected pocket homology […]